Sriram Venneti

Professor

University of Michigan
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends.Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG.Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201.Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial.Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability.Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders.Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls.Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials).Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201.Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201.Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201.Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells.Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase.Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells.Fig. S14. ONC201 increases global H3K27me3 in patient samples.Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2025

Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293

Year:

2025

Adrenocortical carcinoma (ACC) is a rare cancer in which tissue-specific differentiation is paradoxically associated with dismal outcomes. The differentiated ACC subtype CIMP-high is prevalent, incurable, and routinely fatal. CIMP-high ACC possess abnormal DNA methylation and frequent β-catenin–activating mutations. Here, we demonstrated that ACC differentiation is maintained by a balance between nuclear, tissue-specific β-catenin–containing complexes, and the epigenome. On chromatin, β-catenin bound master adrenal transcription factor SF1 and hijacked the adrenocortical super-enhancer landscape to maintain differentiation in CIMP-high ACC; off chromatin, β-catenin bound histone methyltransferase EZH2. SF1/β-catenin and EZH2/β-catenin complexes present in normal adrenals persisted through all phases of ACC evolution. Pharmacologic EZH2 inhibition in CIMP-high ACC expelled SF1/β-catenin from chromatin and favored EZH2/β-catenin assembly, erasing differentiation and restraining cancer growth in vitro and in vivo . These studies illustrate how tissue-specific programs shape oncogene selection, surreptitiously encoding targetable therapeutic vulnerabilities. Significance: Oncogenic β-catenin can use tissue-specific partners to regulate cellular differentiation programs that can be reversed by epigenetic therapies, identifying epigenetic control of differentiation as a viable target for β-catenin–driven cancers.

Year:

2025

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2024

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2024

Adrenocortical carcinoma (ACC) is a rare cancer in which tissue-specific differentiation is paradoxically associated with dismal outcomes. The differentiated ACC subtype CIMP-high is prevalent, incurable, and routinely fatal. CIMP-high ACC possess abnormal DNA methylation and frequent β-catenin activating mutations. Here, we demonstrated that ACC differentiation is maintained by a balance between nuclear, tissue-specific β-catenin-containing complexes and the epigenome. On chromatin, β-catenin bound master adrenal transcription factor SF1 and hijacked the adrenocortical super-enhancer landscape to maintain differentiation in CIMP-high ACC; off chromatin, β-catenin bound histone methyltransferase EZH2. SF1/β-catenin and EZH2/β-catenin complexes present in normal adrenals persisted through all phases of ACC evolution. Pharmacologic EZH2 inhibition in CIMP-high ACC expelled SF1/β-catenin from chromatin and favored EZH2/β-catenin assembly, erasing differentiation and restraining cancer growth in vitro and in vivo. These studies illustrate how tissue-specific programs shape oncogene selection, surreptitiously encoding targetable therapeutic vulnerabilities.

Year:

2024

H3K27M-mutant diffuse midline glioma (DMG) patients have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/CSF correlate samples from patients treated in two completed multi-site clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, while those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle-related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuro-glial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction.

Year:

2024

Collaborators (38)

Matthew Hall

Associate Clinical Professor

Florida International University

UNITED STATES
View details

Chandan Kumar

Associate Research Scientist

University of Michigan

UNITED STATES
View details

Berenice Bilharinho de Mendonca

Professor of Endocrinology

University of Sao Paulo

BRAZIL
View details

Adam Resnick

Director

University of Pennsylvania

UNITED STATES
View details

Sebastian Waszak

Tenure Track Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Mariella Filbin

Dana-Farber Cancer Institute

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Yoshie Umemura

Barrow Neurological Institute

UNITED STATES
View details

Rajen J. Mody

University of Michigan

UNITED STATES
View details

minesh mehta

Chair

Florida International University

UNITED STATES
View details

Anna Schwendeman

-

UNITED STATES
View details

Timothy Cloughesy

Director of NeuroOncology Program/Professor

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Michelle M Kim

University of Michigan

UNITED STATES
View details

Lili Zhao

Professor

Northwestern University

UNITED STATES
View details

Charles Burant

University of Michigan

UNITED STATES
View details

Sabine Mueller

Adjunt Associate Professor

University of California

UNITED STATES
View details

Nathalie Agar

Principal Investigator

Brigham and Women's Hospital

UNITED STATES
View details

Tobias Else

University of Michigan

UNITED STATES
View details

Rajan Jain

Professor

NYU Langone Health

UNITED STATES
View details

Matthew Dun

Professor Paediatric Heamatology/Oncology Research

Hunter Medical Research Institute

AUSTRALIA
View details

Antonio Marcondes Lerario

University of Michigan

UNITED STATES
View details

Susanne Schmidt

Group Leader

University of Bonn

GERMANY
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Andrea T. Franson

-

UNITED STATES
View details

Javad Nazarian

Lead, DMG Research Center

-

SWITZERLAND
View details

William E Rainey

University of Michigan

UNITED STATES
View details

Chan Chung

Principal investigator

Daegu Gyeongbuk Institute of Science and Technology

SOUTH KOREA
View details

Richard J Auchus

University of Michigan

UNITED STATES
View details

Benjamin M Ellingson

Professor

University of California, Los Angeles

UNITED STATES
View details

David breault

Harvard University

UNITED STATES
View details

Derek Dang

University of Michigan

UNITED STATES
View details

Thomas Giordano

Professor

University of Michigan

UNITED STATES
View details

Christopher LaPensee

University of Michigan

UNITED STATES
View details

Daniel R. Wahl

University of Michigan

UNITED STATES
View details

Gary D. Hammer

University of Michigan

UNITED STATES
View details

Jacques Grill

Head day care

Gustave Roussy

FRANCE
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details

Sharon L Gardner

Associate Professor (Clinical) of Pediatrics

NYU School of Medicine

UNITED STATES
View details